← Leaderboards
Michael R. Farzan
Boston Children'S Hospital
$72,884,755
Attributed
$81,975,264
Total exposure
56
Grants
50
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13.2M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$107,786,445 · 58
By mechanism
R01$34,226,229 · 12
U19$30,047,119 · 5
P01$15,247,789 · 3
R37$9,174,632 · 1
R44$5,532,417 · 2
DP1$4,800,000 · 1
Top collaborators
- Michael David Alpert7 shared
- Eric Andrew Appel6 shared
- Hyeryun None Choe3 shared
- Joseph L Mankowski3 shared
- David T Curiel2 shared
- Mauricio De Aguiar Martins2 shared
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionAntibodiesHiv-1Neutralizing AntibodyViralProteinsVirusMacaca MulattaMediatingAdeno-Associated Viral VectorSimian Human Immunodeficiency VirusDependovirusCellsPreventMacacaVariantInhibitor/AntagonistIn VivoGlycoproteinsLaboratoriesBaseAffinityTransgenesReceptor
Grant awards (168)
Vectored HIV Immunotherapy via in vivo B cell editing$1,272,001
R01 · FY2025 · AI
Therapeutic use of an enhanced form of CD4-Ig$884,356
R37 · FY2025 · AI · contact PI
An Env apex-focused HIV-1 vaccine strategy$867,099
R01 · FY2025 · AI · contact PI
In vivo transformation of chimeric antigen receptor B cells for a functional cure of HIV$833,420
R01 · FY2025 · AI · contact PI
eCD4-Mediated Control of SIV Infection in the Brain$830,924
R01 · FY2025 · NS · contact PI
Engineering CAR-B cells for an HIV-1 functional cure$686,549
R01 · FY2025 · DA · contact PI
An AAV-mediated functional cure and its impact on the reservoir$2,431,122
U19 · FY2024 · AI · contact PI
Core B: Non-human primate core$1,860,432
U19 · FY2024 · AI · contact PI
Vectored HIV Immunotherapy via in vivo B cell editing$1,289,517
R01 · FY2024 · AI
An Env apex-focused HIV-1 vaccine strategy$891,681
R01 · FY2024 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$884,320
R37 · FY2024 · AI · contact PI
eCD4-Mediated Control of SIV Infection in the Brain$848,349
R01 · FY2024 · NS · contact PI
In vivo transformation of chimeric antigen receptor B cells for a functional cure of HIV$824,985
R01 · FY2024 · AI · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$793,531
R01 · FY2024 · AI · contact PI
Project 4: A permanent off-switch for AAV$740,799
U19 · FY2024 · AI · contact PI
Engineering CAR-B cells for an HIV-1 functional cure$651,390
R01 · FY2024 · DA · contact PI
Safe, CRISPR/Cas-free B cell editing for therapeutic applications$265,500
R21 · FY2024 · AI · contact PI
Improving mRNA vaccines with extracellular vesicle-associated immunogens$221,250
R21 · FY2024 · AI · contact PI
Core A: Administrative Core$47,006
U19 · FY2024 · AI · contact PI
An AAV-mediated functional cure and its impact on the reservoir$2,609,556
U19 · FY2023 · AI · contact PI
eCD4-mediated control of SIV infection in the brain$914,116
R01 · FY2023 · NS · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$837,265
R01 · FY2023 · AI · contact PI
In vivo transformation of chimeric antigen receptor B cells for a functional cure of HIV$790,719
R01 · FY2023 · AI · contact PI
Engineering CAR-B cells for an HIV-1 functional cure$741,117
R01 · FY2023 · DA · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$721,724
R37 · FY2023 · AI · contact PI
Core B: Non-human primate core$552,027
U19 · FY2023 · AI · contact PI
Project 4: A permanent off-switch for AAV$354,250
U19 · FY2023 · AI · contact PI
Safe, CRISPR/Cas-free B cell editing for therapeutic applications$221,250
R21 · FY2023 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$200,125
R37 · FY2023 · AI · contact PI
Improving mRNA vaccines with extracellular vesicle-associated immunogens$189,627
R21 · FY2023 · AI · contact PI
Improving mRNA vaccines with extracellular vesicle-associated immunogens$82,817
R21 · FY2023 · AI · contact PI
Core A: Administrative Core$47,008
U19 · FY2023 · AI · contact PI
Targeting druggable coronavirus proteins$5,786,835
U19 · FY2022 · AI · contact PI
An AAV-mediated functional cure and its impact on the reservoir$3,136,852
U19 · FY2022 · AI · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$838,771
R01 · FY2022 · AI · contact PI
Engineering CAR-B cells for an HIV-1 functional cure$695,020
R01 · FY2022 · DA · contact PI
Project 4: A permanent off-switch for AAV$671,571
U19 · FY2022 · AI · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$643,832
R37 · FY2022 · AI · contact PI
Core B: Non-human primate core$602,735
U19 · FY2022 · AI · contact PI
Core A: Administrative Core$565,431
U19 · FY2022 · AI · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$275,287
R37 · FY2022 · AI · contact PI
An AAV-mediated functional cure and its impact on the reservoir$2,834,491
U19 · FY2021 · AI · contact PI
Core B: Non-human primate core$1,802,558
U19 · FY2021 · AI · contact PI
Project 4: A permanent off-switch for AAV$963,326
U19 · FY2021 · AI · contact PI
A safety switch for an effective HIV-1 vaccine$960,000
DP1 · FY2021 · DA · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$924,262
R37 · FY2021 · AI · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$846,301
R01 · FY2021 · AI · contact PI
Core A: Administrative Core$716,441
U19 · FY2021 · AI · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$674,085
R01 · FY2021 · AI · contact PI
Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apex$277,500
R21 · FY2021 · AI · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$24,596
R01 · FY2021 · AI · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$1
R01 · FY2021 · AI · contact PI
An AAV-mediated functional cure and its impact on the reservoir$2,938,902
U19 · FY2020 · AI · contact PI
Development of AAV vectors for long-term expression of eCD4-Ig$999,443
R44 · FY2020 · AI
A safety switch for an effective HIV-1 vaccine$960,000
DP1 · FY2020 · DA · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$941,035
R01 · FY2020 · AI · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$882,067
R37 · FY2020 · AI · contact PI
Core B: Non-human primate core$877,027
U19 · FY2020 · AI · contact PI
An injectable hydrogel platform for sustained release of eCD4-Ig$874,862
R01 · FY2020 · AI · contact PI
Project 4: A permanent off-switch for AAV$462,500
U19 · FY2020 · AI · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$343,458
R01 · FY2020 · AI · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$331,181
R01 · FY2020 · AI · contact PI
Eliciting tyrosine-sulfated neutralizing antibodies recognizing the Env apex$231,250
R21 · FY2020 · AI · contact PI
Core A: Administrative Core$46,250
U19 · FY2020 · AI · contact PI
Development of AAV vectors for long-term expression of eCD4-Ig$999,675
R44 · FY2019 · AI
A safety switch for an effective HIV-1 vaccine$960,000
DP1 · FY2019 · DA · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$940,275
R01 · FY2019 · AI · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$934,552
R37 · FY2019 · AI · contact PI
Development of AAV vectors for long-term expression of eCD4-Ig$999,959
R44 · FY2018 · AI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$998,663
R44 · FY2018 · AI
A safety switch for an effective HIV-1 vaccine$960,000
DP1 · FY2018 · DA · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$943,250
R37 · FY2018 · AI · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$941,073
R01 · FY2018 · AI · contact PI
Optimizing eCD4-Ig for eradication and a functional cure$966,508
R01 · FY2017 · AI · contact PI
A safety switch for an effective HIV-1 vaccine$960,000
DP1 · FY2017 · DA · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$951,702
R37 · FY2017 · AI · contact PI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$937,245
R44 · FY2017 · AI
Development of AAV vectors for long-term expression of eCD4-Ig$299,239
R44 · FY2017 · AI
A Gene therapeutic approach to stable suppression of HIV-1 replication$2,381,501
P01 · FY2016 · AI · contact PI
Therapeutic Use of an Enhanced Form of CD4-Ig$929,155
R37 · FY2016 · AI · contact PI
Viral escape from AAV expressed transgenes$627,941
P01 · FY2016 · AI · contact PI
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?$298,193
R44 · FY2016 · AI
Administrative$45,962
P01 · FY2016 · AI · contact PI
A Gene therapeutic approach to stable suppression of HIV-1 replication$2,422,882
P01 · FY2015 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$842,384
R01 · FY2015 · AI · contact PI
Viral escape from AAV expressed transgenes$633,146
P01 · FY2015 · AI · contact PI
Administrative$69,287
P01 · FY2015 · AI · contact PI
A Gene therapeutic approach to stable suppression of HIV-1 replication$2,442,349
P01 · FY2014 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$955,860
R01 · FY2014 · AI · contact PI
Viral escape from AAV expressed transgenes$670,121
P01 · FY2014 · AI · contact PI
Administrative$63,621
P01 · FY2014 · AI · contact PI
A Gene therapeutic approach to stable suppression of HIV-1 replication$2,388,013
P01 · FY2013 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$847,177
R01 · FY2013 · AI · contact PI
Viral escape from AAV expressed transgenes$691,130
P01 · FY2013 · AI · contact PI
A double-mimetic inhibitor of HIV-1 entry$531,952
R01 · FY2013 · AI · contact PI
The In Vivo Relevance and Therapeutic Applications of the IFITM Proteins$398,386
U54 · FY2013 · AI · contact PI
Administrative$84,217
P01 · FY2013 · AI · contact PI
A Gene therapeutic approach to stable suppression of HIV-1 replication$2,225,513
P01 · FY2012 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$786,427
R01 · FY2012 · AI · contact PI
Viral escape from AAV expressed transgenes$441,853
P01 · FY2012 · AI · contact PI
The In Vivo Relevance and Therapeutic Applications of the IFITM Proteins$330,112
U54 · FY2012 · AI · contact PI
A double-mimetic inhibitor of HIV-1 entry$237,100
R01 · FY2012 · AI · contact PI
A double-mimetic inhibitor of HIV-1 entry$188,387
R01 · FY2012 · AI · contact PI
Administrative$60,253
P01 · FY2012 · AI · contact PI
Therapeutic use of an enhanced form of CD4-Ig$849,236
R01 · FY2011 · AI · contact PI
A double-mimetic inhibitor of HIV-1 entry$424,506
R01 · FY2011 · AI · contact PI
Indentification and characterization of cellular receptors for enveloped viruses$418,975
U54 · FY2011 · AI · contact PI
TYROSINE-SULFATED PEPTIDE DERIVED FROM HIV-1 ANTIBODY INHIBITS HIV-1 INFECTION$210,597
P51 · FY2011 · RR · contact PI
TRANSFERRIN RECEPTOR 1 IS A CELLULAR RECEPTOR FOR NEW WORLD HEMORRHAGIC FEVER AR$166,443
P51 · FY2011 · RR · contact PI
RECEPTOR-BINDING DOMAINS OF FILOVIRUSES BIND A COMMON RECEPTOR$166,443
P51 · FY2011 · RR · contact PI
INFLUENZA A VIRUS NEURAMINIDASE LIMITS VIRAL SUPERINFECTION$166,443
P51 · FY2011 · RR · contact PI
Indentification and characterization of cellular receptors for enveloped viruses$436,526
U54 · FY2010 · AI · contact PI
A double-mimetic inhibitor of HIV-1 entry$427,928
R01 · FY2010 · AI · contact PI
RECEPTOR-BINDING DOMAINS OF FILOVIRUSES BIND A COMMON RECEPTOR$202,435
P51 · FY2010 · RR · contact PI
TYROSINE-SULFATED PEPTIDE DERIVED FROM HIV-1 ANTIBODY INHIBITS HIV-1 INFECTION$202,435
P51 · FY2010 · RR · contact PI
TRANSFERRIN RECEPTOR 1 IS A CELLULAR RECEPTOR FOR NEW WORLD HEMORRHAGIC FEVER AR$202,435
P51 · FY2010 · RR · contact PI
INFLUENZA A VIRUS NEURAMINIDASE LIMITS VIRAL SUPERINFECTION$202,435
P51 · FY2010 · RR · contact PI
A double-mimetic inhibitor of HIV-1 entry$449,500
R01 · FY2009 · AI · contact PI
Indentification and characterization of cellular receptors for enveloped viruses$391,900
U54 · FY2009 · AI · contact PI
Tyrosine Sulfation in HIV-1 and SIV Entry$347,278
R01 · FY2009 · AI · contact PI
TYROSINE-SULFATED PEPTIDE DERIVED FROM HIV-1 ANTIBODY INHIBITS HIV-1 INFECTION$206,081
P51 · FY2009 · RR · contact PI
RECEPTOR-BINDING DOMAINS OF FILOVIRUSES BIND A COMMON RECEPTOR$159,013
P51 · FY2009 · RR · contact PI
TRANSFERRIN RECEPTOR 1 IS A CELLULAR RECEPTOR FOR NEW WORLD HEMORRHAGIC FEVER AR$159,013
P51 · FY2009 · RR · contact PI
INFLUENZA A VIRUS NEURAMINIDASE LIMITS VIRAL SUPERINFECTION$159,013
P51 · FY2009 · RR · contact PI
STUDIES OF A SARS-CORONAVIRUS RECEPTOR$468,555
R01 · FY2008 · AI · contact PI
Tyrosine Sulfation in HIV-1 and SIV Entry$347,278
R01 · FY2008 · AI · contact PI
Phage-based selection of tyrosine-sulfated entry inhibitors$255,305
R21 · FY2008 · AI · contact PI
Core--Bioinformatics and Technology Facility$201,806
P30 · FY2008 · AI · contact PI
TRANSFERRIN RECEPTOR 1 IS A CELLULAR RECEPTOR FOR NEW WORLD HEMORRHAGIC FEVER AR$32,442
P51 · FY2008 · RR · contact PI
RECEPTOR-BINDING DOMAINS OF FILOVIRUSES BIND A COMMON RECEPTOR$32,442
P51 · FY2008 · RR · contact PI
TYROSINE-SULFATED PEPTIDE DERIVED FROM HIV-1 ANTIBODY INHIBITS HIV-1 INFECTION$32,442
P51 · FY2008 · RR · contact PI
S PROTEINS OF HCOV-NL63 SARS COV OVERLAPPING ACE2 REGIONS$32,442
P51 · FY2008 · RR · contact PI
INFLUENZA A VIRUS NEURAMINIDASE LIMITS VIRAL SUPERINFECTION$32,442
P51 · FY2008 · RR · contact PI
STUDIES OF A SARS-CORONAVIRUS RECEPTOR$477,629
R01 · FY2007 · AI · contact PI
Tyrosine Sulfation in HIV-1 and SIV Entry$354,004
R01 · FY2007 · AI · contact PI
Toward a new world monkey model of HIV-1 infection$239,449
R21 · FY2007 · AI · contact PI
Phage-based selection of tyrosine-sulfated entry inhibitors$216,875
R21 · FY2007 · AI · contact PI
Core--Bioinformatics and Technology Facility$196,436
P30 · FY2007 · AI · contact PI
Tyrosine Sulfation in HIV-1 and SIV entry$169,000
R01 · FY2007 · AI · contact PI
MASS SPECTROMETRIC CHARACTERIZATION OF SULFATED ANTI-HIV ANTIBODIES$58,033
P51 · FY2007 · RR · contact PI
TOWARD A NEW WORLD PRIMATE MODEL OF HIV INFECTION$58,032
P51 · FY2007 · RR · contact PI
STRUCTURE/FUNCTION STUDIES OF THE SARS CORONVIRUS RECEPTOR$31,561
P51 · FY2007 · RR · contact PI
Tyrosine Sulfation in HIV-1 and SIV Entry$364,577
R01 · FY2006 · AI · contact PI
STUDIES OF A SARS-CORONAVIRUS RECEPTOR$313,213
R01 · FY2006 · AI · contact PI
Toward a new world monkey model of HIV-1 infection$204,350
R21 · FY2006 · AI · contact PI
Core--Bioinformatics and Technology Facility$190,801
P30 · FY2006 · AI · contact PI
MASS SPECTOMETRIC CHARACTERIZATION OF ANTI-HIV ANTIBODIES$134,807
P51 · FY2006 · RR · contact PI
TOWARD A NEW WORLD PRIMATE MODEL OF HIV INFECTION$134,807
P51 · FY2006 · RR · contact PI
STRUCTURE/FUNCTION STUDIES OF THE SARS CORONVIRUS RECEPTOR$55,933
P51 · FY2006 · RR · contact PI
STUDIES OF A SARS-CORONAVIRUS RECEPTOR$320,750
R01 · FY2005 · AI
Tyrosine Sulfation in HIV-1 and SIV Entry$308,550
R01 · FY2005 · AI
Tyrosine Sulfation in HIV-1 and SIV Entry$302,750
R01 · FY2004 · AI
Characterization of BACE and BACE2 Beta-Secretases$258,557
R01 · FY2004 · AG
ANTI-GP120 ANTIBODIES RECOGNIZING THE CCR5 BINDIGN SITE$241,250
R21 · FY2004 · AI
STUDIES OF A SARS-CORONAVIRUS RECEPTOR$183,744
R01 · FY2004 · AI
STUDIES OF A SARS-CORONAVIRUS RECEPTOR$136,008
R01 · FY2004 · AI
Characterization of BACE and BACE2 Beta-Secretases$44,193
R01 · FY2004 · AG
Tyrosine Sulfation in HIV-1 and SIV Entry$302,750
R01 · FY2003 · AI
Characterization of BACE and BACE2 Beta-Secretases$302,750
R01 · FY2003 · AG
ANTI-GP120 ANTIBODIES RECOGNIZING THE CCR5 BINDING SITE$241,250
R21 · FY2003 · AI
Characterization of BACE and BACE2 Beta-Secretases$296,553
R01 · FY2002 · AG
HIV GP 120 AND HETEROLOGOUS T CELL HELPER EPITOPES$178,479
R21 · FY2002 · AI
Tyrosine Sulfation in HIV-1 and SIV Entry$170,353
R01 · FY2002 · AI
Tyrosine Sulfation in HIV-1 and SIV Entry$129,407
R01 · FY2002 · AI
HIV GP 120 AND HETEROLOGOUS T CELL HELPER EPITOPES$53,662
R21 · FY2002 · AI
Tyrosine Sulfation in HIV-1 and SIV Entry$300,636
R01 · FY2001 · AI
Characterization of BACE and BACE2 Beta-Secretases$297,408
R01 · FY2001 · AG
HIV GP 120 AND HETEROLOGOUS T CELL HELPER EPITOPES$235,334
R21 · FY2001 · AI